A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibitor

被引：0
|
作者：
Wang, J. [1 ]
Shen, Y. [1 ]
Chen, J. [2 ]
Chen, X. [3 ]
Guan, Q. [4 ]
Liu, Q. [5 ]
Xu, J. [6 ]
Xu, Y. [7 ]
Zhang, B. [8 ]
Zhang, H. [9 ]
Zhu, Y. [10 ]
Zhang, Y. [11 ]
机构：
[1] Jiangsu Canc Hosp, Gynecol, Nanjing, Peoples R China
[2] Second Peoples Hosp Changzhou, Gynecol, Changzhou, Jiangsu, Peoples R China
[3] First Peoples Hosp Yancheng, Gynecol, Yancheng, Peoples R China
[4] Jiangsu Hosp Tradit Chinese Med, Gynecol, Nanjing, Peoples R China
[5] Nanjing Med Univ, Jiangning Hosp, Gynecol, Nanjing, Peoples R China
[6] Subei Peoples Hosp Jiangsu Prov, Gynecol, Yangzhou, Jiangsu, Peoples R China
[7] First Peoples Hosp Changzhou, Gynecol, Changzhou, Jiangsu, Peoples R China
[8] Fourth Peoples Hosp Xuzhou, Xuzhou Cent Hosp, Gynecol, Xuzhou, Jiangsu, Peoples R China
[9] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Gynecol, Nanjing, Peoples R China
[10] Xuzhou Third Peoples Hosp, Xuzhou Canc Hosp, Gynecol, Xuzhou, Jiangsu, Peoples R China
[11] First Peoples Hosp Lianyungang, Gynecol, Lianyungang, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202P
引用
收藏
页码：S1513 / S1513
页数：1
相关论文
共 50 条
  • [1] Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
    Takehara, Kazuhiro
    Matsumoto, Takashi
    Hamanishi, Junzo
    Hasegawa, Kosei
    Matsuura, Motoki
    Miura, Kiyonori
    Nagao, Shoji
    Nakai, Hidekatsu
    Tanaka, Naotake
    Tokunaga, Hideki
    Ushijima, Kimio
    Watari, Hidemichi
    Yokoyama, Yoshihito
    Kase, Yoichi
    Sumino, Shuuji
    Suri, Ajit
    Itamochi, Hiroaki
    Takeshima, Nobuhiro
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (02) : 1 - 11
  • [2] Efficacy and safety of niraparib combined with anlotinib maintenance retreatment in platinum-sensitive recurrent ovarian cancer patients who previously received PARP inhibitor: An open-label, single-arm, prospective, exploratory phase II study
    Jin, Ying
    Pan, Lingya
    Shan, Ying
    Li, Yan
    Gu, Yu
    Wang, Wei
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S168 - S168
  • [3] A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)
    Cho, Hyun-Woong
    Park, Jeong-Yeol
    Kim, Byoung Gie
    Kim, Jae-Weon
    Lim, Myong Cheol
    Jeong, Dae Hoon
    Lee, Jung-Yun
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A9 - A9
  • [4] Platinum-sensitive ovarian cancer recurrence after PARP-inhibitor maintenance at first line: a real-world scenario
    Loverro, Matteo
    Marchetti, Claudia
    Capomacchia, Filippo Maria
    Caricato, Chiara
    Giannarelli, Diana
    Scambia, Giovanni
    Fagotti, Anna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A397 - A397
  • [5] Efficacy of subsequent chemotherapy regimens in platinum-sensitive recurrent ovarian cancer following PARP inhibitor progression: a multicenter retrospective study
    Zhao, Yuxi
    Kang, Haili
    Zhao, Hongwei
    Wang, Li
    Duan, Wei
    Wu, Lingying
    Zuo, Jing
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A76 - A78
  • [6] OPINION: A single-arm, open-label, phase IIIb study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm)
    Poveda, A. M.
    Davidson, R.
    Blakeley, C.
    Milner, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Apatinib, a novel VEGFR inhibitor, combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer: A single-arm, open-label, phase 2 study
    Lan, Chunyan
    Wang, Yin
    Xiong, Ying
    Li, Judong
    Li, Yanfang
    Zhang, Yanna
    Zheng, Min
    Feng, Yanling
    Huang, Huiqiang
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer
    Li, Ning
    Bu, Hualei
    Liu, Jihong
    Zhu, Jianqing
    Zhou, Qi
    Wang, Li
    Yin, Rutie
    Wu, Xiaohua
    Yao, Shuzhong
    Gu, Kangsheng
    Zhang, Hui
    Li, Guiling
    Pan, Hongming
    Wu, Qiang
    An, Ruifang
    Yang, Xinfeng
    Zhu, Yaping
    Wan, Xiaoping
    Duan, Wei
    Xiong, Jianping
    Guo, Hongyan
    Lou, Ge
    Wang, Jing
    Hu, Wenjing
    Zhang, Xin
    Meng, Yuanguang
    Zhang, Ben
    Wang, Yuting
    Wang, Quanren
    Wu, Lingying
    CLINICAL CANCER RESEARCH, 2021, 27 (09) : 2452 - 2458
  • [9] Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy
    Xing, Puyuan
    Wang, Mengzhao
    Zhao, Jun
    Zhong, Wei
    Chi, Yujia
    Xu, Ziyi
    Li, Junling
    THORACIC CANCER, 2021, 12 (20) : 2825 - 2828
  • [10] Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
    Zhao, Y.
    Liu, J.
    Li, X.
    Li, Y.
    Pu, H.
    Wang, X.
    Yang, M.
    Bai, S.
    Guo, L.
    Zhao, L.
    Zhang, M.
    Zhao, H.
    Xu, S.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1674 - S1674
12345